TrialClinical cancer research : an official journal of the American Association for Cancer Research2024

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.

Kathy S Albain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.